作为RNA靶向递送的核心配体，GalNAc-L96在siRNA和ASO疗法中发挥着关键作用。凭借领先的合成技术、严格的质量控制以及强大的定制化能力，沃尔森在该领域具有显著的竞争优势，助力RNA递送技术的突破与发展。 返回搜狐，查看更多 ...

GalNAc-L96：高效RNA靶向递送的关键分子 ...

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first ...

为解决肝癌治疗难题，复旦大学附属肿瘤医院的研究人员开展 FAM99B 相关研究。发现 FAM99B 可抑制核糖体生成和肝癌进展，GalNAc - FAM99B65 - 146 有治疗潜力。该研究为肝癌治疗提供新思路，值得科研人员阅读。 复旦大学附属肿瘤医院（Fudan University Shanghai Cancer Center ...

Reports Q4 revenue $83.748M vs $29.056M. “2024 was an exceptional year for Wave and we’ve continued the positive momentum into 2025, with the ...

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

WAVE Life Sciences Ltd (WVE) reports a strong Q4 with significant revenue growth and promising clinical progress, despite ...

Q4 2024 Earnings Call Transcript March 4, 2025 Wave Life Sciences Ltd. beats earnings expectations. Reported EPS is $0.17, expectations were $-0.17. Operator: Good morning and welcome to the Wave Life ...